Based on this frame, we investigated the relationship between the CYP3A5*3 and CYP3A4*1G genotypes in liver transplant donors and recipients, and on the pharmacokinetics of Tac, and on the complication of liver transplantation (e.g. new-onset diabetes and new-onset hypertension), considering the known clinical determinants of Tac disposition. This evidence concerns the gene CYP3A4 and Hypertension.